Publications by authors named "Bryan D Anderson"

Claim this Profile
T
Thermal Reshaping Dynamics of Gold Nanorods: Influence of Size, Shape, and Local Environment.
William J Kennedy, Sarah Izor, Bryan D Anderson, Geoffrey Frank, Vikas Varshney

ACS Appl Mater Interfaces· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.
Jonathan M Yingling, William T McMillen, Lei Yan, Huocong Huang, J Scott Sawyer, Bryan D Anderson

Oncotarget· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and chemical transformation of Ni nanoparticles embedded in silica.
Brian B Lynch, Bryan D Anderson, W Joshua Kennedy, Joseph B Tracy

Nanoscale· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanoparticle conversion chemistry: Kirkendall effect, galvanic exchange, and anion exchange.
Bryan D Anderson, Joseph B Tracy

Nanoscale· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity.
Robert M Campbell, Bryan D Anderson, Nathan A Brooks, Harold B Brooks, Edward M Chan

Mol Cancer Ther· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Airbrushed nickel nanoparticles for large-area growth of vertically aligned carbon nanofibers on metal (Al, Cu, Ti) surfaces.
Mehmet F Sarac, Bryan D Anderson, Ryan C Pearce, Justin G Railsback, Adedapo A Oni

ACS Appl Mater Interfaces· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transfer of vertically aligned carbon nanofibers to polydimethylsiloxane (PDMS) while maintaining their alignment and impalefection functionality.
Ryan C Pearce, Justin G Railsback, Bryan D Anderson, Mehmet F Sarac, Timothy E McKnight

ACS Appl Mater Interfaces· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
Hong-Yu Li, William T McMillen, Charles R Heap, Denis J McCann, Lei Yan, Bryan D Anderson

J Med Chem· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties.
Mary Mader, Alfonso de Dios, Chuan Shih, Rosanne Bonjouklian, Tiechao Li, Bryan D Anderson

Bioorg Med Chem Lett· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.
Hong-yu Li, Yan Wang, Charles R Heap, Chi-Hsin R King, Sreenivasa R Mundla, Bryan D Anderson

J Med Chem· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases.
Chafiq Hamdouchi, Boyu Zhong, Jose Mendoza, Elizabeth Collins, Carlos Jaramillo, Bryan D Anderson

Bioorg Med Chem Lett· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy.
Alfonso de Dios, Chuan Shih, Beatriz López de Uralde, Concepción Sánchez, Miriam del Prado, Bryan D Anderson

J Med Chem· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The development of potent and selective bisarylmaleimide GSK3 inhibitors.
Thomas A Engler, Sushant Malhotra, Timothy P Burkholder, James R Henry, David Mendel, Bryan D Anderson

Bioorg Med Chem Lett· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.
Carlos Jaramillo, J Eugenio de Diego, Chafiq Hamdouchi, Elizabeth Collins, Heather Keyser, Bryan D Anderson

Bioorg Med Chem Lett· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
J Scott Sawyer, Douglas W Beight, Karen S Britt, Bryan D Anderson, Robert M Campbell

Bioorg Med Chem Lett· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel and potent transforming growth factor beta type I receptor kinase domain inhibitor: 7-amino 4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines.
Hong-yu Li, Yan Wang, Lei Yan, Robert M Campbell, Bryan D Anderson

Bioorg Med Chem Lett· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo[1,2-a]pyridines.
Chafiq Hamdouchi, Heather Keyser, Elizabeth Collins, Carlos Jaramillo, Jose Eugenio De Diego, Bryan D Anderson

Mol Cancer Ther· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
J Scott Sawyer, Bryan D Anderson, Douglas W Beight, Robert M Campbell, Michael L Jones

J Med Chem· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles.
Thomas A Engler, Kelly Furness, Sushant Malhotra, Concha Sanchez-Martinez, Chuan Shih, Bryan D Anderson

Bioorg Med Chem Lett· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.
Guoxin Zhu, Scott E Conner, Xun Zhou, Chuan Shih, Tiechao Li, Bryan D Anderson

J Med Chem· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis